Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mepolizumab (SB240563) in respiratory disease
jRCT2080223689Phase 3Completed
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3 trial of mepolizumab in bronchopulmonary diseases. Started Oct 2017; status: completed.
02
Drugs
mepolizumab
03
Conditions
bronchopulmonary diseases
Beyond the preview
Go deeper on jRCT2080223689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223689.